Pfizer agreed to pay Innovent Biologics $650 million upfront for rights to 12 early-stage cancer drug programs, with total deal value reaching $10.5 billion including milestone payments.
Back
Pfizer and Innovent Biologics sign $10.5B cancer drug deal
Pfizer agreed to pay Innovent Biologics $650 million upfront for rights to 12 early-stage cancer drug programs.
"This collaboration brings together two highly complementary engines of innovation with a shared ambition to move faster, go further and deliver truly transformative medicines to patients who are waiting," Jeff Legos, Chief Oncology Officer at Pfizer, said.
The deal covers eight Innovent-originated programs and four Pfizer-proposed discovery assets, including antibody-drug conjugates with novel payloads and multi-specific antibodies. Innovent will lead development through Phase 1, after which Pfizer takes over global development. The companies will co-develop and share costs on four programs, with profit-sharing in the US and Europe.
The $10.5 billion total potential value — including up to $9.85 billion in milestone payments and tiered double-digit royalties — confirms Innovent's early-stage oncology capabilities and shows Pfizer's commitment to expanding its ADC and multi-specific antibody pipeline. The transaction is expected to close in the third quarter, subject to regulatory approvals.
Under the agreement's three-tier structure, Pfizer receives an exclusive global license for four programs and bears full development costs. For another four, Pfizer gets exclusive rights outside Greater China and funds the majority of development. The remaining four will be co-developed globally, with both companies sharing costs and co-commercializing in the US and Europe while Innovent retains Greater China rights.
"This agreement brings together best-in-industry expertise of Pfizer and Innovent to advance novel cancer medicines to patients at a global scale," Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) at Innovent, said.
The deal provides Innovent with significant near-term capital to fund its pipeline. The Suzhou-based biotech has launched 18 products and has five assets in Phase 3 or pivotal trials, with 14 more in early-stage development.
For Pfizer, the deal strengthens its oncology pipeline with 12 early-stage assets at a time when the industry is racing to develop next-generation ADCs and multi-specific antibodies. Investors will watch for Phase 1 data readouts from the partnered programs over the next 12 to 18 months.
This article is for informational purposes only and does not constitute investment advice.
